Royalty Report: Drugs, Cancer, Therapeutic – Collection: 2928

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 6

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 6

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Disease
  • Biotechnology
  • Pharmaceuticals
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 2928

License Grant
An Australian licensor and a U.S. clinical development oncology company (majority owned by licensor) have concluded a Licence Agreement for licensee to develop and commercialize the oncology compound NV-128.
License Property
NV-128 is a cancer compound which has been shown in pre-clinical studies to promote cancer cell death in multi-drug resistant cancer cells by inducing caspase – independent DNA degradation and cancer cell death via the AKT-mTOR pathway.
Field of Use
Licensee will fund the ongoing clinical programs and is responsible for the commercial development of the drug.  Licensee is also the licensee of the licensor developed investigational anti-cancer drugs phenoxodiol and triphendiol that are currently in clinical development.

IPSCIO Record ID: 25982

License Grant
The Licensee, a subsidiary of the Licensor, entered into a License Agreement with the Licensor, granting an exclusive, worldwide, non-transferable License under its patents and patent applications and in the intellectual property rights related to its know how, to conduct clinical trials, commercialize and distribute NV-128.
License Property
NV-128 is an investigational cancer compound which has been shown in pre-clinical laboratory studies to promote cancer cell death by targeting a pro-survival regulatory pathway (the AKT-mTOR pathway). The NV-128 License Agreement covers the use of NV-128 in the field of prevention, treatment and cure of cancer in humans delivered in all forms except topical applications.

IPSCIO Record ID: 3954

License Grant
The Parties, one U.S. and the other Japanese, desire and intend to collaborate with respect to the Development and Commercialization of Products in the Field in the Territory.
License Property
Two pharmaceutical companies entered into a global agreement to develop and commercialize MDV3100, a investigational drug for the treatment of prostate cancer.  MDV3100 is currently being evaluated in the Phase 3 AFFIRM clinical trial in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.

MDV3100 is currently being evaluated in the Phase 3 AFFIRM clinical trial in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.

MDV3100, a new generation of oral anti-androgen, which shows different pharmacological profiles from current anti-androgens, has been shown in preclinical studies to provide more complete suppression of the androgen receptor pathway than bicalutamide, the most commonly used anti-androgen. MDV3100 slows growth and induces cell death in bicalutamide-resistant cancers via three complementary actions – MDV3100 blocks testosterone binding to the androgen receptor, impedes movement of the androgen receptor to the nucleus of prostate cancer cells (nuclear translocation), and inhibits binding to DNA. Preclinical data published in Science earlier this year demonstrated that MDV3100 is superior to bicalutamide in each of these three actions.

Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 197886

License Grant
The company acquired the substance KB9520 from Licensor.
License Property
In pre-clinical studies the substance has shown that it contributes to reduced adverse effects of cytotoxic treatment when intake of KB9520 and cytotoxic treatment are combined. KB9520 has also proved to have a good effect on several different types of cancer in pre-clinical models. In these disease models, treatment has proved to result in a significant reduction in tumour size by stimulating apoptosis (programmed cell death) and inhibiting cell growth.
Field of Use
This agreement pertains to the drug industry relating to cytotoxic treatment as well as cancer.

IPSCIO Record ID: 211579

License Grant
The Company received exclusive development and commercialization rights worldwide to MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1). MGA012 is currently in clinical development by Licensor.
License Property
MGA012 is an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1). MGA012 is currently in clinical development by Licensor.
Field of Use
This agreement pertains to the drug industry.
Antibodies targeting PD-1 have shown clinical efficacy in the treatment of various tumors. These antibodies act as checkpoint inhibitors, releasing the “brakes” on the immune system that are often imposed by tumors as a means to evade immune detection.

IPSCIO Record ID: 203444

License Grant
The Canadian Licensor grants to the Israeli Licensee an exclusive, even as to Licensor, right and license throughout the Territory, with the right to grant sublicenses, under the Licensor Intellectual Property:
– to Develop, have Developed, make, have made, and use the Licensed Compound and Licensed Product in the Field, and
– to sell, offer for sale, register, Commercialize and otherwise exploit the Licensed Product in the Field; provided that notwithstanding the exclusive rights granted to Licensee in the foregoing grant, Licensor shall retain the limited right to use the Licensor Intellectual Property to the extent necessary to perform its express obligations under this Agreement, including the Clinical Development Plan,  to conduct the Licensor Clinical Studies,  subject to the approval of the Joint Steering Committee, and as otherwise agreed to in writing by the Parties.

The exclusivity of the sublicense granted under such Licensor Intellectual Property is subject to the applicable non-exclusivity terms in the another Agreement.

Included with this agreement is also a non-exclusive, non-sublicensable, except to subcontractors as
permitted under this Agreement, solely to permit such subcontractors to perform Licensors assigned responsibilities under the Clinical Development Plan, royalty-free, fully-paid right and license, by Licensee to Licensor under the Licensee Know-How and Licensee Patent Rights, solely to the extent necessary to conduct the activities assigned to Licensor by the Joint Steering Committee under the Clinical Development Plan.

License Property
The licensed property includes:
TRPM-2 Antisense Therapy;
TRPM-2 Antisense Therapy and Combination composition;
TRPM-2 Antisense Therapy Using ai Oligonucleotide Having 2-0-(2- Methoxy)Ethyl Modifications Compound;
Chemo-and radiation-sensitization or cancer by antisense TRPM-2 oligodcoxynucleotides;
Treatment of Melanoma by Reduction in Clusterin Levels;
Clusterin antisense therapy for treatment of cancer;
Treatment of Cancer By Perturbation of Clusterin Levels;
Human Type 2 RNASE H;
Gapped Oligonucleotides, Directed to: Gapmer and Hemimer Compounds with 2-O-ALKYL modifications;
2-O-Modified Nucleosides and Phosphoramidites; and others.

The collaboration agreement is for developing and commercializing OGX-011. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance. OGX-011 is expected to be used as adjunct therapy to enhance the effectiveness of chemotherapy and has shown promising results when added to currently available chemotherapies in several tumor types addressing a significant unmet medical need.

Field of Use
The Field means the prevention, diagnosis or treatment of any disease or medical condition in humans.  Specific fields addressed in the patents include prostate cancer cells, human renal cell cancer (RCC) cells and some breast cancer cells.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.